FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Willingham

Research Profile

Living Beings

Anatomy

Chemicals & Drugs

Procedures

Immunohistochemistry

Physiology

Co-author Network

Publications

TOP 3
Laura Fozzatti; Anthony N Hollenberg; Dong Wook Kim; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α.
Bhavani Krishnan; Thomas L Smith; E Ann Tallant; Frank M Torti; Mark C Willingham; Michael E Zapadka; Purnima Dubey; Patricia E Gallagher
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Won Gu Kim; Changxue Lu; Jeong Won Park; Mark C Willingham; Laura Fozzatti; Celine J Guigon; Sheue-Yann Cheng
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Willingham (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Laura Fozzatti; Anthony N Hollenberg; Dong Wook Kim; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(19):7850-5.
2013: Bhavani Krishnan; Thomas L Smith; E Ann Tallant; Frank M Torti; Mark C Willingham; Michael E Zapadka; Purnima Dubey; Patricia E Gallagher
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
The Prostate 2013;73(1):71-82.
2012: Won Gu Kim; Changxue Lu; Jeong Won Park; Mark C Willingham; Laura Fozzatti; Celine J Guigon; Sheue-Yann Cheng
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(5):1281-90.
2011: Zachary D Cary; Mark C Willingham; Douglas S Lyles
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Journal of virology 2011;85(12):5708-17.
2011: Michael Blanks; Jonathan M Adams; Glenn O Allen; Wei Du; Jennifer Hu; James Lovato; Istvan Molnar; John R Stehle; Mark C Willingham; Zheng Cui
Novel innate cancer killing activity in humans.
Cancer cell international 2011;11():26.
2011: Haiguo Sun; Mark C Willingham; Martha Wilson; Yong Q Chen; Zhennan Gu; Yunping Hu; Lawrence L Rudel; Iris J Edwards
Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.
PloS one 2011;6(5):e20502.
2010: Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
Cancer research 2010;70(22):9084-94.
2010: Zandra K Pinnix; Lance D Miller; Wei Wang; Ralph D'Agostino; Tim Kute; Mark C Willingham; Heather Hatcher; Lia Tesfay; Guangchao Sui; Xiumin Di; Suzy V Torti; Frank M Torti
Ferroportin and iron regulation in breast cancer progression and prognosis.
Science translational medicine 2010;2(43):43ra56.
2010: Heather Alger; J Mark Brown; Janet K Sawyer; Kathryn L Kelley; Ramesh Shah; Martha Wilson; Mark C Willingham; Lawrence L Rudel
Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization.
The Journal of biological chemistry 2010;285(19):14267-74.
2010: Elizabeth J Akins; Miranda L Moore; Shuai Tang; Mark C Willingham; Janet A Tooze; Purnima Dubey
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Cancer research 2010;70(9):3473-82.
2010: Ali Mallakin; Takayuki Sugiyama; Fumitake Kai; Pankaj Taneja; Robert D Kendig; Donna P Frazier; Dejan Maglic; Lauren A Matise; Mark C Willingham; Kazushi Inoue
The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1.
International journal of cancer. Journal international du cancer 2010;126(6):1403-16.
2010: Kimberly R Blish; Kathryn A Clausen; Gregory A Hawkins; A Julian Garvin; Mark C Willingham; Julie C Turner; Frank M Torti; Suzy V Torti
Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.
Journal of experimental & clinical cancer research : CR 2010;29():147.
2010: Gregory Riedlinger; Jonathan Adams; John R Stehle; Michael Blanks; Anne M Sanders; Amy M Hicks; Mark C Willingham; Zheng Cui
The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction.
BMC cancer 2010;10():179.
2010: Anne M Sanders; John R Stehle; Michael Blanks; Gregory Riedlinger; Jung W Kim-Shapiro; Arta M Monjazeb; Jonathan M Adams; Mark C Willingham; Zheng Cui
Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements.
BMC cancer 2010;10():121.
2010: Mark C Willingham
Fluorescence labeling of intracellular antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 2010;588():153-64.
2010: Mark C Willingham
Fluorescence labeling of surface antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 2010;588():143-51.
2009: John R Stehle; Michael Blanks; Gregory Riedlinger; Jung W Kim-Shapiro; Anne M Sanders; Jonathan M Adams; Mark C Willingham; Zheng Cui
Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice.
BMC cancer 2009;9():328.
2008: Wei Du; Zheng Cui; Zhao-Chun Tsui; Qirui Chen; Mark C Willingham
In situ immunocytochemical detection of altered membrane composition induced by cell-cell contact in cultured mammalian cells.
Microscopy research and technique 2008;71(10):749-59.
2008: Xuewei Zhu; Ji-Young Lee; Jenelle M Timmins; J Mark Brown; Elena Boudyguina; Anny Mulya; Abraham K Gebre; Mark C Willingham; Elizabeth M Hiltbold; Nilamadhab Mishra; Nobuyo Maeda; John S Parks
Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages.
The Journal of biological chemistry 2008;283(34):22930-41.
2008: Rhonda E Wooten; Mark C Willingham; Larry W Daniel; Christina C Leslie; LeAnn C Rogers; S Sergeant; Joseph T O'Flaherty
Novel translocation responses of cytosolic phospholipase A2alpha fluorescent proteins.
Biochimica et biophysica acta 2008;1783(8):1544-50.
2008: Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Role of DMP1 and its future in lung cancer diagnostics.
Expert review of molecular diagnostics 2008;8(4):435-47.
2008: Lan G Coffman; Julie C Brown; David A Johnson; Narayanan Parthasarathy; Ralph B D'Agostino; Mark Lively; Xiaoyang Hua; Stephen L Tilley; Werner Muller-Esterl; Mark C Willingham; Frank M Torti; Suzy V Torti
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin.
American journal of physiology. Lung cellular and molecular physiology 2008;294(3):L505-15.
2008: Ashley E Weant; Ryan Michalek; Islam U Khan; Beth C Holbrook; Mark C Willingham; Jason M Grayson
Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction.
Immunity 2008;28(2):218-30.
2008: Kimberly Rose Blish; Wei Wang; Mark C Willingham; Wei Du; Charles E Birse; Surekha R Krishnan; Julie C Brown; Gregory A Hawkins; A Julian Garvin; Ralph B D'Agostino; Frank M Torti; Suzy V Torti
A human bone morphogenetic protein antagonist is down-regulated in renal cancer.
Molecular biology of the cell 2008;19(2):457-64.
2008: Beth O Van Emburgh; Jennifer Hu; Edward A Levine; Libyadda J Mosley; L Douglas Case; Hui-Yi Lin; Sommer N Knight; Nancy D Perrier; Peter Rubin; Gary B Sherrill; Cindy S Shaw; Lisa A Carey; Lynda R Sawyer; Glenn O Allen; Clara Milikowski; Mark C Willingham; Mark Steven Miller
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.
Molecular carcinogenesis 2008;47(2):88-99.
2007: Ali Mallakin; Takayuki Sugiyama; Pankaj Taneja; Lauren A Matise; Donna P Frazier; Mayur Choudhary; Gregory A Hawkins; Ralph B D'Agostino; Mark C Willingham; Kazushi Inoue
Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.
Cancer cell 2007;12(4):381-94.
2007: Ryan E Temel; Weiqing Tang; Yinyan Ma; Lawrence L Rudel; Mark C Willingham; Yiannis A Ioannou; Joanna P Davies; Lisa-Mari Nilsson; Liqing Yu
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.
The Journal of clinical investigation 2007;117(7):1968-78.
2007: Manal Zabalawi; Manish S Bharadwaj; Heather Horton; Mark Cline; Mark C Willingham; Michael J Thomas; Mary G Sorci-Thomas
Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance?
Journal of lipid research 2007;48(1):52-65.
2007: John R Stehle; mark e weeks; Kai Lin; Mark C Willingham; Amy M Hicks; John Francis Timms; Zheng Cui
Mass spectrometry identification of circulating alpha-1-B glycoprotein, increased in aged female C57BL/6 mice.
Biochimica et biophysica acta 2007;1770(1):79-86.
2006: Ali Mallakin; Pankaj Taneja; Lauren A Matise; Mark C Willingham; Kazushi Inoue
Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs.
Oncogene 2006;25(59):7703-13.
2006: Amy M Hicks; Gregory Riedlinger; Mark C Willingham; Martha Alexander-Miller; Chris Von Kap-Herr; Mark J Pettenati; Anne M Sanders; Holly M Weir; Wei Du; Joseph Kim; Andrew J G Simpson; Lloyd J Old; Zheng Cui
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(20):7753-8.
2006: Liqing Yu; Shantaram Bharadwaj; J Mark Brown; Yinyan Ma; Wei Du; Matthew A Davis; Peter Michaely; Pingsheng Liu; Mark C Willingham; Lawrence L Rudel
Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake.
The Journal of biological chemistry 2006;281(10):6616-24.
2006: John R Stehle; Mark C Willingham; Kai Lin; Zheng Cui
A nonterminal method for frequent collection of mouse circulating proteins by peritoneal lavage.
Analytical biochemistry 2006;349(1):162-4.
2006: Amy M Hicks; Mark C Willingham; Wei Du; Changlee S Pang; Lloyd J Old; Zheng Cui
Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice.
Cancer immunity 2006;6():11.
2005: Joseph T O'Flaherty; LeAnn C Rogers; Christian Paumi; Roy R Hantgan; Lance R Thomas; Carl Clay; Kevin High; Yong Q Chen; Mark C Willingham; Pamela K Smitherman; Timothy E Kute; Anuradha Rao; Scott D Cramer; Charles S Morrow
5-Oxo-ETE analogs and the proliferation of cancer cells.
Biochimica et biophysica acta 2005;1736(3):228-36.
2005: You-Jun Shen; Cynthia J DeLong; Francois Tercé; Timothy E Kute; Mark C Willingham; Mark J Pettenati; Zheng Cui
Polyploid formation via chromosome duplication induced by CTP:phosphocholine cytidylyltransferase deficiency and Bcl-2 overexpression: identification of two novel endogenous factors.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2005;53(6):725-33.
2005: Anthony J Bleyer; Thomas Hart; Mark C Willingham; Samy S Iskandar; Michael C Gorry; Howard Trachtman
Clinico-pathologic findings in medullary cystic kidney disease type 2.
Pediatric nephrology (Berlin, Germany) 2005;20(6):824-7.
2005: Tie Fu Liu; Philip D Hall; Kimberley A Cohen; Mark C Willingham; Jiaozhong Cai; Andrew Thorburn; Arthur E Frankel
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):329-34.
2004: Marlena M Westcott; Ralph J Abi-Habib; Kimberley A Cohen; Mark C Willingham; Shihui Liu; Thomas H Bugge; Stephen H Leppla; Arthur E Frankel
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells.
Molecular cancer therapeutics 2004;3(12):1681-9.
2004: Paolo Parini; Matthew Davis; Aaron T Lada; Sandra K Erickson; Teresa L Wright; Ulf Gustafsson; Staffan Sahlin; Curt Einarsson; Mats Eriksson; Bo Angelin; Hiroshi Tomoda; Satoshi Omura; Mark C Willingham; Lawrence L Rudel
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver.
Circulation 2004;110(14):2017-23.
2004: Jian Li; Juan Codina; Elizabeth Petroske; Mike J Werle; Mark C Willingham; Thomas D DuBose
The effect of beta-subunit assembly on function and localization of the colonic H+,K+-ATPase alpha-subunit.
Kidney international 2004;66(3):1068-75.
2004: Zheng Cui; Mark C Willingham
Halo naevus: a visible case of immunosurveillance in humans?
The lancet oncology 2004;5(7):397-8.
2004: Shaila Bhat; Manal Zabalawi; Mark C Willingham; Gregory S Shelness; Michael J Thomas; Mary G Sorci-Thomas
Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions.
Journal of lipid research 2004;45(7):1207-20.
2004: Gary G Schwartz; Dawn Eads; Anuradha Rao; Scott D Cramer; Mark C Willingham; Tai C Chen; Daniel P Jamieson; Lilin Wang; Kerry L Burnstein; Michael F Holick; Constantinos Koumenis
Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3.
Carcinogenesis 2004;25(6):1015-26.
2004: Zheng Cui; Mark C Willingham
The effect of aging on cellular immunity against cancer in SR/CR mice.
Cancer immunology, immunotherapy : CII 2004;53(6):473-8.
2004: István Molnár; Timothy E Kute; Mark C Willingham; Gary G Schwartz
19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations.
The Journal of steroid biochemistry and molecular biology 2004;89-90(1-5):539-43.
2004: Jacqueline K Trupiano; Kim R Geisinger; Mark C Willingham; Paul Manders; Nora Zbieranski; Doug Case; Edward A Levine
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2004;17(4):476-81.
2004: Mian Xu; Heather S Floyd; Suzanne M Greth; Wen-Chi L Chang; Kurt Lohman; Radka Stoyanova; Gregory Kucera; Tim E Kute; Mark C Willingham; Mark Steven Miller
Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects.
Toxicology and applied pharmacology 2004;195(2):232-46.
2004: Timothy E Kute; Christopher M Lack; Mark C Willingham; Bimjhana Bishwokama; Holly Williams; Kathy Barrett; Tanita Mitchell; James P Vaughn
Development of Herceptin resistance in breast cancer cells.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2004;57(2):86-93.
2004: Jeffrey O Urieto; TieFu Liu; Jennifer H Black; Kimberley A Cohen; Philip D Hall; Mark C Willingham; Lewis K Pennell; Donna E Hogge; Robert J Kreitman; Arthur E Frankel
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Protein expression and purification 2004;33(1):123-33.
2004: Andrew J Sweatt; Mac Wood; Agus Suryawan; Reidar Wallin; Mark C Willingham; Susan M Hutson
Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves.
American journal of physiology. Endocrinology and metabolism 2004;286(1):E64-76.
2003: Tie Fu Liu; Mark C Willingham; Stephen B Tatter; Kimberley A Cohen; A Corinne Lowe; Andrew Thorburn; Arthur E Frankel
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Bioconjugate chemistry 2003;14(6):1107-14.
2003: Tie Fu Liu; Kimberley A Cohen; Mark C Willingham; Stephen B Tatter; Raj K Puri; Arthur E Frankel
Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
Journal of neuro-oncology 2003;65(1):77-85.
2003: gira Raval; Shantaram Bharadwaj; Edward A Levine; Mark C Willingham; Randolph L Geary; Tim Kute; Gaddamanugu L Prasad
Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors.
Oncogene 2003;22(40):6194-203.
2003: Yurong Yang Wheeler; Timothy E Kute; Mark C Willingham; Si-Yi Chen; David C Sane
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(12):1733-5.
2003: Manal Zabalawi; Shaila Bhat; Tara Loughlin; Michael J Thomas; Eric Alexander; Mark Cline; Bill Bullock; Mark C Willingham; Mary G Sorci-Thomas
Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol.
The American journal of pathology 2003;163(3):1201-13.
2003: Tie Fu Liu; Stephen B Tatter; Mark C Willingham; Mitchell Yang; Jennifer Hu; Arthur E Frankel
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy.
Molecular cancer therapeutics 2003;2(8):783-7.
2003: Zheng Cui; Mark C Willingham; Amy M Hicks; Martha Alexander-Miller; Timothy Howard; Gregory A Hawkins; Mark Steven Miller; Holly M Weir; Wei Du; Cynthia J DeLong
Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(11):6682-7.
2003: Tie Fu Liu; Kimberley A Cohen; Jason G Ramage; Mark C Willingham; Andrew Thorburn; Arthur E Frankel
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells.
Cancer research 2003;63(8):1834-7.
2003: István Molnár; Timothy E Kute; Mark C Willingham; Bayard L Powell; William Dodge; Gary G Schwartz
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.
Journal of cancer research and clinical oncology 2003;129(1):35-42.
2003: Jennifer H Black; JA McCubrey; Mark C Willingham; Jason G Ramage; Donna E Hogge; Arthur E Frankel
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Leukemia 2003;17(1):155-9.
2002: Wendy N Wade; Mark C Willingham; Constantinos Koumenis; Scott D Cramer
p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts.
The Journal of biological chemistry 2002;277(40):37301-6.
2002: Kalyankar Mahadev; gira Raval; Shantaram Bharadwaj; Mark C Willingham; Ethan M Lange; Barbara K Vonderhaar; David Salomon; Gaddamanugu L Prasad
Suppression of the transformed phenotype of breast cancer by tropomyosin-1.
Experimental cell research 2002;279(1):40-51.
2002: Changnian Liu; Mark C Willingham; Jinqian Liu; William H Gmeiner
Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
International journal of oncology 2002;21(2):303-8.
2002: Bryan T Greene; Jacqueline Thorburn; Mark C Willingham; Andrew Thorburn; Roy P Planalp; Martin W Brechbiel; Jamie E Jennings-Gee; John C Wilkinson; Frank M Torti; Suzy V Torti
Activation of caspase pathways during iron chelator-mediated apoptosis.
The Journal of biological chemistry 2002;277(28):25568-75.
2002: Aaron T Lada; Mark C Willingham; Richard W St Clair
Triglyceride depletion in THP-1 cells alters cholesteryl ester physical state and cholesterol efflux.
Journal of lipid research 2002;43(4):618-28.
2002: Suzy V Torti; Meg Golden-Fleet; Mark C Willingham; Rong Ma; Mark Cline; Yoshiro Sakimoto; Frank M Torti
Use of green fluorescent protein to measure tumor growth in an implanted bladder tumor model.
The Journal of urology 2002;167(2 Pt 1):724-8.
2001: R D Abeysinghe; Bryan T Greene; R Haynes; Mark C Willingham; Jolyn Turner; Roy P Planalp; Martin W Brechbiel; Frank M Torti; Suzy V Torti
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
Carcinogenesis 2001;22(10):1607-14.
2001: K L Barrett; J M Willingham; A Julian Garvin; Mark C Willingham
Advances in cytochemical methods for detection of apoptosis.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2001;49(7):821-32.
2001: M Kiser; JA McCubrey; Linda Steelman; John G Shelton; Jason G Ramage; Richard L Alexander; Gregory Kucera; M Pettenati; Mark C Willingham; Mark Steven Miller; Arthur E Frankel
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Leukemia 2001;15(5):814-8.
2000: Richard G Lee; Mark C Willingham; Matthew A Davis; K A Skinner; Lawrence L Rudel
Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates.
Journal of lipid research 2000;41(12):1991-2001.
2000: Nancy Jones; Jerry W Reagan; Mark C Willingham
The pathogenesis of foam cell formation: modified LDL stimulates uptake of co-incubated LDL via macropinocytosis.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(3):773-81.
1999: AJ Trimboli; B Moseley Waite; GI Atsumi; Alfred Fonteh; Andrew M Namen; Carl Clay; Timothy E Kute; Kevin P High; Mark C Willingham; Floyd H Chilton
Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells.
Cancer research 1999;59(24):6171-7.
1999: Carl Clay; Andrew M Namen; GI Atsumi; Mark C Willingham; Kevin P High; Timothy E Kute; AJ Trimboli; Alfred Fonteh; P A Dawson; Floyd H Chilton
Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells.
Carcinogenesis 1999;20(10):1905-11.
1999: Mark C Willingham
Conditional epitopes. is your antibody always specific?
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1999;47(10):1233-6.
1999: Mark C Willingham
Cytochemical methods for the detection of apoptosis.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1999;47(9):1101-10.
1999: CE Hotchkiss; Philip D Hall; J Mark Cline; Mark C Willingham; Robert J Kreitman; J Gardin; A Latimer; Jason G Ramage; Theodore Feely; Stephen J Delatte; Edward P Tagge; Arthur E Frankel
Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Toxicology and applied pharmacology 1999;158(2):152-60.
1999: Arthur E Frankel; Jason G Ramage; A Latimer; Theodore Feely; Stephen J Delatte; Philip D Hall; Edward P Tagge; Robert J Kreitman; Mark C Willingham
High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Protein expression and purification 1999;16(1):190-201.
1999: Nancy Jones; Mark C Willingham
Modified LDLs are internalized by macrophages in part via macropinocytosis.
The Anatomical record 1999;255(1):57-68.
1999: Nancy Jones; N S Allen; Mark C Willingham; J C Lewis
Modified LDLs induce and bind to membrane ruffles on macrophages.
The Anatomical record 1999;255(1):44-56.
1999: Gian G Re; Debra J Hazen-Martin; R El Bahtimi; Noel A Brownlee; Mark C Willingham; A Julian Garvin
Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
International journal of cancer. Journal international du cancer 1999;84(2):192-200.
1999: Philip D Hall; Mark C Willingham; Robert J Kreitman; Arthur E Frankel
DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
Leukemia 1999;13(4):629-33.
1999: Bhagavathi A Narayanan; O Geoffroy; Mark C Willingham; Gian G Re; Daniel W Nixon
p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells.
Cancer letters 1999;136(2):215-21.
1999: Cynthia A Schandl; S Li; Gian G Re; Weimin Fan; Mark C Willingham
Mitotic chromosomal bcl-2. II. Localization to interphase nuclei.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1999;47(2):151-8.
1999: Cynthia A Schandl; S Li; Gian G Re; Weimin Fan; Mark C Willingham
Mitotic chromosomal bcl-2. I. Stable expression throughout the cell cycle and association with isolated chromosomes.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1999;47(2):139-49.
1999: M C Miller; KR Johnson; Mark C Willingham; Weimin Fan
Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest.
Cancer chemotherapy and pharmacology 1999;44(6):444-52.
1999: Mark C Willingham
Fluorescence labeling of intracellular antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 1999;115():121-30.
1999: Mark C Willingham
Fluorescence labeling of surface antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 1999;115():113-9.
1998: Gary B Rosson; Debra J Hazen-Martin; Jaclyn A Biegel; Mark C Willingham; A Julian Garvin; Betty W Oswald; Luanne M Wainwright; Noel A Brownlee; Cynthia F Wright
Establishment and molecular characterization of five cell lines derived from renal and extrarenal malignant rhabdoid tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1998;11(12):1228-37.
1998: Philip D Hall; Robert J Kreitman; Mark C Willingham; Arthur E Frankel
Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
Toxicology and applied pharmacology 1998;150(1):91-7.
1997: Arthur E Frankel; Philip D Hall; C Burbage; Jana Vesely; Mark C Willingham; Kapil N Bhalla; Robert J Kreitman
Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
Blood 1997;90(9):3654-61.
1997: KR Johnson; L Wang; M C Miller; Mark C Willingham; Weimin Fan
5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1739-45.
1997: Edward P Tagge; B Harris; C Burbage; Philip D Hall; Jana Vesely; Mark C Willingham; A Frankel
Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking.
Bioconjugate chemistry 1997;8(5):743-50.
1997: Arthur E Frankel; Joseph H Laver; Mark C Willingham; Linda J Burns; John H Kersey; Daniel A Vallera
Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Leukemia & lymphoma 1997;26(3-4):287-98.
1997: C Burbage; Edward P Tagge; B Harris; Philip D Hall; T Fu; Mark C Willingham; Arthur E Frankel
Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Leukemia research 1997;21(7):681-90.
1997: J A Collins; C A Schandi; K K Young; Jana Vesely; Mark C Willingham
Major DNA fragmentation is a late event in apoptosis.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1997;45(7):923-34.
1997: Arthur E Frankel; T Fu; C Burbage; Edward P Tagge; B Harris; Jana Vesely; Mark C Willingham
Lectin-deficient ricin toxin intoxicates cells bearing the D-mannose receptor.
Carbohydrate research 1997;300(3):251-8.
1997: Gian G Re; Mark C Willingham; R el Bahtimi; Noel A Brownlee; Debra J Hazen-Martin; A Julian Garvin
Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1997;10(2):129-36.
1997: Arthur E Frankel; T Fu; C Burbage; John C. Chandler; Mark C Willingham; Edward P Tagge
IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor.
Leukemia 1997;11(1):22-30.
1996: T Fu; C Burbage; Edward P Tagge; Thomas E Brothers; Mark C Willingham; Arthur E Frankel
Ricin toxin contains three lectin sites which contribute to its in vivo toxicity.
International journal of immunopharmacology 1996;18(12):685-92.
1996: Arthur E Frankel; C Burbage; T Fu; Edward P Tagge; John C. Chandler; Mark C Willingham
Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Biochemistry 1996;35(47):14749-56.
1996: T Fu; C Burbage; Edward P Tagge; John C. Chandler; Mark C Willingham; A Frankel
Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain.
Bioconjugate chemistry 1996;7(6):651-8.
1996: Arthur E Frankel; C Burbage; T Fu; Edward P Tagge; John C. Chandler; Mark C Willingham
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor.
Protein engineering 1996;9(10):913-9.
1996: Timothy S Vincent; Gian G Re; Debra J Hazen-Martin; B I Tarnowski; Mark C Willingham; A Julian Garvin
All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor.
Pediatric pathology & laboratory medicine : journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association 1996;16(5):777-89.
1996: Edward P Tagge; John C. Chandler; B Harris; M Czako; Laszlo Marton; Mark C Willingham; C Burbage; Lawrence B Afrin; Arthur E Frankel
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Protein expression and purification 1996;8(1):109-18.
1996: Gian G Re; C Waters; L Poisson; Mark C Willingham; K Sugamura; Arthur E Frankel
Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells.
Cancer research 1996;56(11):2590-5.
1996: A Frankel; Edward P Tagge; John C. Chandler; C Burbage; Mark C Willingham
Double-site ricin B chain mutants retain galactose binding.
Protein engineering 1996;9(4):371-9.
1996: R el Bahtimi; Debra J Hazen-Martin; Gian G Re; Mark C Willingham; A Julian Garvin
Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1996;9(3):238-44.
1996: Edward P Tagge; John C. Chandler; B L Tang; W Hong; Mark C Willingham; A Frankel
Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1996;44(2):159-65.
1996: A Frankel; Edward P Tagge; John C. Chandler; C Burbage; G Hancock; Jana Vesely; Mark C Willingham
Characterization of single site ricin toxin B chain mutants.
Bioconjugate chemistry 1996;7(1):30-7.
1995: A Frankel; Edward P Tagge; John C. Chandler; C Burbage; G Hancock; Jana Vesely; Mark C Willingham
IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells.
Bioconjugate chemistry 1995;6(6):666-72.
1995: Arthur E Frankel; Edward P Tagge; Mark C Willingham
Clinical trials of targeted toxins.
Seminars in cancer biology 1995;6(5):307-17.
1995: G Kumar; S Ray; Thomas Walle; Huang Yudai; Mark C Willingham; Sally Self; Kapil N Bhalla
Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol.
Cancer chemotherapy and pharmacology 1995;36(2):129-35.
1994: A Frankel; H Roberts; H Gulick; Lawrence B Afrin; Jana Vesely; Mark C Willingham
Expression of ricin B chain in Spodoptera frugiperda.
The Biochemical journal 1994;303 ( Pt 3)():787-94.
1994: Lawrence B Afrin; H Gulick; Jana Vesely; Mark C Willingham; Arthur E Frankel
Expression of oligohistidine-tagged ricin B chain in Spodoptera frugiperda.
Bioconjugate chemistry 1994;5(6):539-46.
1994: C Tang; Mark C Willingham; J C Reed; T Miyashita; Swapan K Ray; V Ponnathpur; Huang Yudai; M E Mahoney; G Bullock; Kapil N Bhalla
High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells.
Leukemia 1994;8(11):1960-9.
1994: Mark C Willingham; Kapil N Bhalla
Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1994;42(4):441-50.
1994: Mark C Willingham
Fluorescence labeling of intracellular antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 1994;34():131-42.
1994: Mark C Willingham
Fluorescence labeling of surface antigens of attached or suspended tissue-culture cells.
Methods in molecular biology (Clifton, N.J.) 1994;34():123-30.